Generic Triglide Availability
Last updated on July 7, 2021.
TRIGLIDE (fenofibrate - tablet;oral)
Manufacturer: SKYEPHARMA AG
Approval date: May 7, 2005
Strength(s): 50MG (discontinued), 160MG [RLD] [BX]
Has a generic version of Triglide been approved?
No. There is currently no therapeutically equivalent version of Triglide available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Spray drying process and compositions of fenofibrate
Issued: February 24, 2004
Inventor(s): Gary W.; Pace & Awadesh K.; Mishra & Robert A.; Snow & Indu; Parikh & Pol-Henri W.; Guivarc'h
Assignee(s): RTP Pharma Inc.
The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
Patent expiration dates:
- September 11, 2021✓✓✓
- September 11, 2021
More about Triglide (fenofibrate)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- En Español
- Drug class: fibric acid derivatives
- FDA Approval History
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.